Kimberly-Clark agrees to buy Tylenol owner Kenvue in $48.7 billion deal, creating consumer staples giant

Kimberly-Clark agrees to buy Tylenol owner Kenvue in .7 billion deal, creating consumer staples giant


Huggies, manufactured by Kimberly-Clark and Band-Aid, manufactured by Kenvue.

Getty Images

Kimberly-Clark announced Monday it’s struck an agreement to buy Kenvue in a deal valued at $48.7 billion that would create a consumer staples giant.

The deal is a combination of cash and stock. Shares of Kenvue surged 20% in premarket trading Monday, while shares of Kimberly-Clark plunged 14%.

The combined company would bring together brands like Huggies and Kleenex with the likes of Band-Aid and Tylenol. It would include 10 billion-dollar brands, the companies said in a news release. The acquisition would be one of the largest on Wall Street this year.

The transaction is expected to close in the second half of 2026.

Kimberly-Clark Chairman and CEO Mike Hsu said in a statement that the companies share a “commitment to developing science and technology to provide extraordinary care.”

“Over the last several years, Kimberly-Clark has undertaken a significant transformation to pivot our portfolio to higher-growth, higher-margin businesses while rewiring our organization to work smarter and faster,” Hsu said. “We have built the foundation and this transaction is a powerful next step in our journey.”

Kenvue, a portfolio of consumer health brands, spun out of Johnson & Johnson in May 2023. Since then, shares have fallen almost 35% from their initial public offering price. As of Friday’s close, Kenvue traded at about $14 per share for a market cap of roughly $27 billion.

Kenvue Chair Larry Merlo said in a statement that following a comprehensive strategic review, the board is “confident this combination represents the best path forward for our shareholders and all other stakeholders.”

Three Kenvue board members will join the Kimberly-Clark board upon the deal’s closing. Hsu will continue to serve as CEO.

The combined company would generate estimated 2025 annual net revenues of roughly $32 billion and adjusted EBITDA of approximately $7 billion, according to the release.

Kimberly-Clark and Kenvue expect about $1.9 billion in cost synergies from the transaction to be realized in the first three years following the deal’s close.



Source

Disney dominated the 2025 box office. Here’s how it could keep the crown in 2026
Business

Disney dominated the 2025 box office. Here’s how it could keep the crown in 2026

Courtesy of Disney Enterprises Inc. Blue aliens, a family of superheroes and a city of talking animals boosted the Walt Disney Company to the top of the domestic box office in 2025. Full-year ticket sales in the United States and Canada rose about 4% from 2024 to $9.05 billion. Disney accounted for the highest share […]

Read More
Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launch
Business

Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launch

A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, US, on Thursday, Jan. 15, 2026. George Frey | Bloomberg | Getty Images Shares of Novo Nordisk rose more than 5% on Friday after early prescription data showed an encouraging start to the U.S. launch of the company’s new GLP-1 pill […]

Read More
Trump’s proposed ban on buying single-family homes introduces uncertainty for family offices
Business

Trump’s proposed ban on buying single-family homes introduces uncertainty for family offices

Single-family homes in a residential neighborhood in Miramar, Florida, Oct. 27, 2022. Joe Raedle | Getty Images News | Getty Images A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Private investment […]

Read More